How Can I Beat the S&P 500? What the Evidence Says
The honest answer to the most asked question in investing: how many people beat the index, why it is so hard, why investors trail even their own funds, and how daily market context fits in.
Carpenter Technology Corporation, basic materials (market value $15.1 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.
Exent re-checks this page every day. Ratings appear 30 days after they are published; the top‑ranked analysts’ calls are not counted here, they are in Gems.
What do the best‑ranked analysts on CRS say now? See it in Exent Gems →
Over the 5 years to Oct 30, 2026, Carpenter Technology Corporation (CRS) returned +865.6% including dividends, versus +75.9% for the S&P 500 (SPY). It beat the index by 789.7 percentage points, or +57.4% a year against +12.0%.
| Period | CRS | S&P 500 | CRS per year | S&P 500 per year | Result |
|---|---|---|---|---|---|
| 1 year | −10.2% | +12.0% | −10.2% | +12.0% | Lagged |
| 3 years | +357.9% | +87.4% | +66.1% | +23.3% | Beat |
| 5 years | +865.6% | +75.9% | +57.4% | +12.0% | Beat |
| 10 years | +949.4% | +316.3% | +26.5% | +15.3% | Beat |
Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.
In the 12 months to 30 days ago, 8 analysts published 79 ratings on CRS. Their latest calls were 88% Buy, 13% Hold and 0% Sell. 5 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.
The consensus 12‑month price target was $461.67 (range $450.00–$470.00), +69.9% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?
| Top‑ranked analyst covering | Firm | Stars | Price‑target hit rate |
|---|---|---|---|
| ??? | ??? | 5.0★ | 70.5% |
| ??? | ??? | 4.9★ | 57.3% |
| Scott Deuschle | Deutsche Bank | 4.8★ | 72.0% |
| Andre Madrid | BTIG | 4.8★ | 66.3% |
| David E. Strauss | Wells Fargo | 4.8★ | 68.6% |
Other analysts covering CRS: Bennett Moore
Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on CRS are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.
The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.
CRS beat the S&P 500 in 6 of the 9 full calendar years shown.
| Year | CRS | S&P 500 | Difference |
|---|---|---|---|
| 2026 (to Oct 30, 2026) | −9.9% | +11.7% | −21.6% |
| 2025 | +86.2% | +17.7% | +68.5% |
| 2024 | +141.7% | +24.9% | +116.8% |
| 2023 | +94.5% | +26.2% | +68.3% |
| 2022 | +29.5% | −18.2% | +47.7% |
| 2021 | +2.7% | +28.7% | −26.0% |
| 2020 | −39.4% | +18.3% | −57.7% |
| 2019 | +42.2% | +31.2% | +11.0% |
| 2018 | −29.2% | −4.6% | −24.6% |
| 2017 | +43.4% | +21.7% | +21.7% |
Over 5 years, CRS had a Sharpe ratio of 1.07 against 0.58 for the S&P 500, so it earned more return per unit of risk than the index. Its annualized volatility was 51.5% and its beta 1.43: it tended to move about 1.4× as much as the market.
| Metric | CRS | S&P 500 |
|---|---|---|
| Annual return | +57.4% | +12.0% |
| Volatility (annualized) | 51.5% | 15.5% |
| Sharpe ratio | 1.07 | 0.58 |
| Sortino ratio | 2.15 | 0.91 |
| Max drawdown (month-end) | −54.1% | −23.9% |
| Beta to the S&P 500 | 1.43 | 1.00 |
CRS’s deepest fall in the crises below was −85.0% in the global financial crisis (2007–09), against −56.5% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.
| Crisis | CRS | S&P 500 | Loss on $100,000 |
|---|---|---|---|
| Global financial crisis (2007–09) | −85.0% | −56.5% | −$84,970 |
| 2018 trade-war selloff | −43.9% | −20.2% | −$43,850 |
| COVID crash (Feb–Mar 2020) | −66.2% | −34.1% | −$66,240 |
| 2022 inflation bear market | −42.2% | −25.4% | −$42,160 |
| 2025 tariff selloff | −28.1% | −19.0% | −$28,110 |
| Window | CRS max drawdown |
|---|---|
| Last 1 year | −56.4% |
| Last 3 years | −56.4% |
| Last 5 years | −56.4% |
| Last 10 years | −75.4% |
Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.
Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, CRS’s correlation with the S&P 500 was 0.43, with the Nasdaq‑100 0.36, with long Treasuries (TLT) 0.29 and with gold (GLD) 0.12.
Adding a 5% CRS position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 16.0%.
| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
|---|---|---|---|
| PFE | −0.16 | HWM | 0.71 |
| CME | −0.15 | GE | 0.60 |
| INTU | −0.07 | AXP | 0.55 |
| ABBV | −0.06 | CAT | 0.54 |
| GILD | −0.05 | BAC | 0.52 |
Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.
| Date | Rating and target | Analyst |
|---|---|---|
| Oct 23 | Target cut Buy | Andre Madrid |
| Oct 14 | Target cut Buy | Bennett Moore |
| Oct 8 | Target cut Buy | Samuel McKinney |
| Sep 30 | Target cut Hold | David E. Strauss |
Named analysts’ rating and price‑target changes on CRS in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.
Of the 89 analyst price targets on CRS set from 2019 until a year ago, 97.8% were reached within 12 months (data to Oct 20, 2026), 29.2 points above the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 95 days. The median target sat 21.7% above the share price on the day it was set.
Where analysts said CRS would be by now: a year ago, 5 analysts had a price target on CRS, and the median of their latest targets was $388.00. On Oct 20, 2026 CRS closed at $372.71, 3.9% below it.
CRS beat the consensus earnings‑per‑share estimate in 11 of its last 12 quarterly reports, through the one on Jul 30, 2026, and the revenue estimate in 4 of 12. From the close before each report to the close after it, the stock moved 8.0% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 5 of the 12 reports. In 5 of the 11 beats the stock still fell.
| Report | EPS vs estimate | Revenue vs estimate | Stock move |
|---|---|---|---|
| Jul 30, 2026 | $3.23 vs $3.09 | −1.4% | −2.1% |
| Apr 29, 2026 | $2.77 vs $2.63 | +1.8% | 0.0% |
| Jan 29, 2026 | $2.33 vs $2.22 | +5.4% | −4.2% |
| Oct 23, 2025 | $2.43 vs $2.13 | +2.2% | +28.4% |
| Jul 31, 2025 | $2.21 vs $2.07 | −4.7% | −9.1% |
| Apr 24, 2025 | $1.88 vs $1.74 | −0.4% | +4.3% |
| Jan 30, 2025 | $1.66 vs $1.56 | −6.5% | −7.7% |
| Oct 24, 2024 | $1.73 vs $1.58 | −3.4% | −0.8% |
Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings
In fiscal 2026 (the year to Jun 30, 2026), CRS’s largest reported region was the United States, with 58.4% of its $3.1 billion revenue. By region: United States 58.4%; Europe 22.4%; Asia Pacific 10.9%; Mexico 4.5%.
By business, the largest segment was Aerospace And Defense Markets, with 65.1% of $3.1 billion revenue (+15.1% on the year before).
| Segment | Revenue | Share | Growth |
|---|---|---|---|
| Aerospace And Defense Markets | $2.0 billion | 65.1% | +15.1% |
| Industrial And Consumer Markets | $401.8 million | 12.9% | +11.8% |
| Medical Market | $278.4 million | 8.9% | −20.7% |
| Energy Market | $230.6 million | 7.4% | +15.1% |
| Transportation Market | $100.4 million | 3.2% | −11.4% |
| Distribution Market | $77.8 million | 2.5% | −7.6% |
From CRS’s annual filings; segment growth compares fiscal 2026 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?
As of Oct 20, 2026, 1 member of Congress had disclosed 3 trades in CRS (3 buys and 0 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated Feb 4, 2026.
| Trade date | Member | Type | Amount |
|---|---|---|---|
| Feb 4, 2026 | Markwayne Mullin | Buy | $15,001–$50,000 |
| Jan 5, 2026 | Markwayne Mullin | Buy | $15,001–$50,000 |
| Jan 5, 2026 | Markwayne Mullin | Buy | $15,001–$50,000 |
Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades
In the 12 months to Oct 20, 2026, CRS insiders made no open‑market purchases and 38 sales worth $93.6 million, according to SEC Form 4 filings. The last open‑market purchase on record was on Mar 26, 2020.
After the 11 insider purchases of $10,000 or more since 2012, CRS beat the S&P 500 by an average of 42.5 percentage points over the next 12 months; 82% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.
| Date | Insider | Role | Value |
|---|---|---|---|
| Mar 26, 2020 | Ligocki Kathleen | Director | $179,025 |
| Mar 24, 2020 | Lain Timothy | VP and Chief Financial Officer | $59,085 |
| Mar 18, 2020 | Thene Tony R | Director, officer: President and CEO | $97,460 |
| Mar 18, 2020 | Malloy Brian J | VP - Chief Commercial Officer | $49,980 |
| Mar 18, 2020 | Dee James D | VP, Gen Counsel & Secretary | $52,890 |
The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?
As of the Sep 30, 2026 settlement date, 2.99% of CRS’s float was sold short: 1.4 million shares, or 1.8 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 6.47%. The median across the 997 US stocks Exent tracks was 4.77%, so CRS is less heavily shorted than most.
From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks
At the end of Q2 2026 (Jun 30, 2026), 910 institutions reported holding CRS in 13F filings, up 182 from the quarter before and up from 609 a year earlier. Their reported holdings add up to 94.3% of CRS’s shares. In the quarter 554 institutions added to their positions and 257 cut them.
Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling
CRS’s diluted share count rose 4.3% over the five fiscal years to fiscal 2026 and fell 0.6% in fiscal 2026 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.
Stock‑based compensation was $26.4 million in fiscal 2026, 0.8% of revenue. CRS spent $179.1 million buying back shares, a buyback yield of 0.80% of its market value; stock pay equaled 14.7% of the buybacks.
Weighted‑average diluted shares from CRS’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained
In Exent’s Oct 20, 2026 snapshot, CRS’s Altman Z‑score was 9.49, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 9 out of 9; 3% of scored stocks reach 9 or more.
The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?
As of Oct 20, 2026, 39 of the 304 ETFs Exent tracks held CRS. Its largest weight is in XAR (State Street SPDR S&P Aerospace & Defense ETF), at 2.57% of the fund.
| ETF | Fund | Weight of CRS |
|---|---|---|
| XAR | State Street SPDR S&P Aerospace & Defense ETF | 2.57% |
| ITA | iShares U.S. Aerospace & Defense ETF | 1.44% |
| PAVE | Global X U.S. Infrastructure Development ETF | 1.13% |
| PPA | Invesco Aerospace & Defense ETF | 1.06% |
| IJK | iShares S&P Mid-Cap 400 Growth ETF | 0.93% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.56% |
| SPMD | State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.55% |
| MDY | State Street SPDR S&P MIDCAP 400 ETF Trust | 0.55% |
Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?
Exent matches every holding to the index with the most similar risk. For CRS that is SPY (the S&P 500). Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.
| Ticker | Name | 5‑year return | Volatility (5y) |
|---|---|---|---|
| SCCO | Southern Copper Corporation | +297.0% | 39.3% |
| NEM | Newmont Corporation | +126.5% | 37.8% |
| FCX | Freeport-McMoRan Inc. | +77.5% | 45.1% |
| CDE | Coeur Mining, Inc. | +107.3% | 69.3% |
| CSL | Carlisle Companies Incorporated | +78.4% | 32.9% |
| RPM | RPM International Inc. | +29.0% | 26.4% |
| MAS | Masco Corporation | +35.1% | 29.7% |
| AXTA | Axalta Coating Systems Ltd. | +9.2% | 31.1% |
Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.
Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
Wall Street’s average CRS price target is 69.9% above the latest share price. See what the best‑ranked analysts on CRS say now in Exent Gems.
Yes. CRS returned +949.4% (+26.5% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.
No. As of Oct 20, 2026, CRS (Carpenter Technology Corporation) is not one of the 503 stocks in the S&P 500.
CRS fell −85.0% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.
CRS fell −66.2% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.
CRS fell −42.2% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.
Over the 5 years to Oct 30, 2026, CRS’s Sharpe ratio was 1.07 and its Sortino ratio 2.15, versus 0.58 and 0.91 for the S&P 500.
CRS’s 5‑year annualized volatility was 47.3%, higher than the S&P 500’s 17.0%, with a beta of 1.43.
Among large US stocks, the lowest correlations with CRS over the last 60 months were PFE (−0.16), CME (−0.15), INTU (−0.07). Its correlation with long Treasuries (TLT) was 0.29 and with gold (GLD) 0.12.
CRS beat the consensus earnings-per-share estimate in 11 of its last 12 quarterly reports through Jul 30, 2026, and the revenue estimate in 4 of 12. The stock moved 8.0% on average, up or down, from the close before each report to the close after it.
Yes. As of Oct 20, 2026, 1 member of Congress had disclosed 3 trades in CRS (3 buys and 0 sales) in STOCK Act disclosures filed with the House and Senate.
As of the Sep 30, 2026 settlement date, 2.99% of CRS’s float was sold short (1.4 million shares, 1.8 days to cover), according to FINRA short-interest reports. A year earlier it was 6.47%.
Yes. CRS’s diluted share count rose 4.3% over the five fiscal years to fiscal 2026 and fell 0.6% in the latest year. Stock-based compensation was 0.8% of revenue, and buybacks totaled $179.1 million.
Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on CRS are, their latest calls and the stocks where several of them agree.
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.